Retrospective cohort study on linezolid in empirical treatment of methicillin-resistant Staphylococcus pneumonia
10.3760/cma.j.issn.1674-2397.2011.03.008
- VernacularTitle:利奈唑胺经验治疗耐甲氧西林葡萄球菌肺炎的回顾性队列研究
- Author:
Cuihua HU
;
Mingtao LIU
;
Xinan WANG
;
Pengpeng YAN
;
Xiuhe OUYANG
- Publication Type:Journal Article
- Keywords:
Pneumonia,Staphyloccal;
Methicillin resistance;
Linezolid;
Empirical treatment
- From:
Chinese Journal of Clinical Infectious Diseases
2011;4(3):159-162
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of linezolid in empirical treatment of methicillin-resistant Staphylococcus (MRS) pneumonia. Methods One hundred and thirty-five hospitalized patients with MSR pneumonia receiving linezolid from April 2009 to October 2010 were enrolled in this retrospective cohort study, and all subjects were assigned to two groups: 75 cases with empirical treatment (linezolid 0. 6 g by infusion q12h at admission) , and 60 cases with objective treatment (linezolid after the sputum culture). The severity score, clinical effect and adverse effect were observed, and the therapeutic effects in patients with high risk factors were especially evaluated. SPSS13.0 software was used for statistical analysis. Results The scores were decreased significantly after finishing therapeutic causes for 3 and 7 days in both groups (tempirical =12.29 and 16.53, tobjective =9.36 and 11.49, P<0. 05). There were significant differences in severity scores after 3 and 7 days between empirical and objective treatment groups (t =2. 64 and 3. 08, P < 0. 01). There were significant differences in absorption time, length of ICU and total hospital stay between two groups (t =6. 61 , 4. 39 and 10. 25, P <0. 05). In empirical and objective group, the effective rates were 88.0% (66/75) and 83.3% (50/60) (x2 = 0.60, P > 0.05 ). In the patients with high risk factors, the effective rates of two groups were 86. 8% (33/38) and 63. 6% (14/22) , and the difference was significant (x2 =4.42, P<0.05). The rate of adverse effects were 6.7% (5/75) in empirical group and 5.0% (3/60) in objective group, and the difference was not significant (x2 =0. 17, P > 0. 05). Conclusion Linezolid can be used as empirical treatment for MRS pneumonia with rapid symptoms relieve and high efficacy, especially for patients with high risk.
